Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Int J Rheum Dis ; 26(3): 591-598, 2023 Mar.
Artículo en Inglés | MEDLINE | ID: covidwho-2251694

RESUMEN

Systemic lupus erythematosus (SLE) has the potential to affect virtually every organ; however, gastrointestinal system manifestations are relatively rare compared to other autoimmune diseases such as systemic sclerosis and inflammatory bowel disease. A 29-year-old female patient attended to the emergency room with abdominal distention, acute onset abdominal pain and constipation. She had watery chronic diarrhea (4-5 times/d) and weight loss (6 kg, 12%) for 4 months. While there was increased intestinal wall thickness, air-liquid levels were shown on abdomen computed tomography scan. The patient underwent abdominal surgery due to diagnosis of ileus. Ileocecal resection was performed and pathologic evaluation revealed intestinal lymphangiectasia. Autoimmune serology was performed with the following resulats: anti-nuclear antibody 1/3200 with homogenous pattern, anti-DNA antibody and anti-Sm/ribonucleoprotein antibodies were positive in addition to low complement levels (C3: 0.28 [0.9-1.8 g/L], C4: 0.06 [0.1-0.4 g/L]) indicating diagnosis of SLE. Development of intestinal involvement in SLE (lupus enteritis) is mainly grouped into 3 headings such as mesenteric vasculitis, pseudo-obstruction, and protein-losing enteropathy. Although the pathogenesis of intestinal lymphangiectasia remains unknown, it has been reported that immune complex-mediated visceral vasculitis may result in bowel wall and mucosal edema. To our knowledge this is the first case report accompanying hyperinflammatory response in addition to intestinal lymphangiectasia in SLE. On the other hand, clinicians should be alert for other reasons for hyperinflammatory syndromes rather than COVID-19, even during the pandemic.


Asunto(s)
COVID-19 , Arteritis de Células Gigantes , Granulomatosis con Poliangitis , Lupus Eritematoso Sistémico , Enteropatías Perdedoras de Proteínas , Femenino , Humanos , Adulto , Enteropatías Perdedoras de Proteínas/etiología , COVID-19/complicaciones , Lupus Eritematoso Sistémico/diagnóstico , Intestinos , Diarrea , Granulomatosis con Poliangitis/complicaciones , Arteritis de Células Gigantes/complicaciones
2.
Dig Dis Sci ; 66(12): 4557-4564, 2021 12.
Artículo en Inglés | MEDLINE | ID: covidwho-1064547

RESUMEN

Collagenous colitis (CC) is associated with non-bloody, watery diarrhea, which is pathophysiologically reasonable because normal colonic absorption (or excretion) of water and electrolytes can be blocked by the abnormally thick collagen layer in CC. However, CC has also been associated with six previous cases of protein-losing enteropathy (PLE), with no pathophysiologic explanation. The colon does not normally absorb (or excrete) amino acids/proteins, which is primarily the function of the small bowel. Collagenous duodenitis (CD) has not been associated with PLE. This work reports a novel case of CD (and CC) associated with PLE; a pathophysiologically reasonable mechanism for CD causing PLE (by the thick collagen layer of CD blocking normal intestinal amino acid absorption); and a novel association of PLE with severe COVID-19 infection (attributed to relative immunosuppression from hypoproteinemia, hypoalbuminemia, hypogammaglobulinemia, and malnutrition from PLE).


Asunto(s)
Aminoácidos/metabolismo , COVID-19/etiología , Colitis Colagenosa/complicaciones , Duodenitis/complicaciones , Duodeno/fisiopatología , Absorción Intestinal , Mucosa Intestinal/fisiopatología , Enteropatías Perdedoras de Proteínas/etiología , Anciano , COVID-19/diagnóstico , COVID-19/fisiopatología , Colitis Colagenosa/diagnóstico , Colitis Colagenosa/fisiopatología , Colitis Colagenosa/terapia , Duodenitis/diagnóstico , Duodenitis/fisiopatología , Duodenitis/terapia , Duodeno/metabolismo , Femenino , Fluidoterapia , Glucocorticoides/uso terapéutico , Humanos , Mucosa Intestinal/metabolismo , Estado Nutricional , Nutrición Parenteral Total , Enteropatías Perdedoras de Proteínas/diagnóstico , Enteropatías Perdedoras de Proteínas/fisiopatología , Enteropatías Perdedoras de Proteínas/terapia , Factores de Riesgo , Resultado del Tratamiento , Tratamiento Farmacológico de COVID-19
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA